Holly Logue

Holly Logue

Of Counsel
hlogue@lrrc.com vCard
626.683.4572 office
4300 Bohannon Drive
Suite 230
Menlo Park, CA 94025

Holly Logue is Of Counsel in the firm’s Intellectual Property practice group, offering strategic patent and intellectual property counseling, procurement, diligence, licensing, transactions and intellectual property solutions to maximize the value of technology companies, including life science, biotechnology, diagnostic, medical device and software companies.

She has served as acting in-house attorney for multiple public and non-public entities, overseeing strategic development of their intellectual property portfolios, including working closely with management teams to implement business development objectives, transactions, negotiations, litigation strategy and employment matters. 

Holly has extensive experience and core strength in negotiating and drafting agreements to manage both complex and simple business transactions at the national and international level, as well as with related employment and regulatory issues. She has represented Fortune 500 companies in numerous transactions, including research collaboration agreements, development and commercialization licenses, clinical research agreements and litigation settlements. 

She is an experienced patent and trade secret litigator, providing guidance to clients to both avoid potential litigation and manage ongoing litigation effectively.

Holly’s experience also includes serving on the professional staff of the Science and Technology Committee, Subcommittee on Technology and Innovation, for the U.S. House of Representatives where she was responsible for overseeing the National Institute of Standards and Technology.

Memberships & Affiliations

  • Women in Bio

Representative Matters

  • Represented an HIV technology company in its negotiations with multiple parties, including the U.S. Navy, to procure various manufacturing technologies for its lead gene therapy treatment.
  • Acted as lead intellectual property and transactional counsel for a privately held diagnostic company focusing on breast and prostate cancer. Lead company successfully through diligence for a major investor, resulting in $32M in private equity funding.
  • Strategically manages intellectual property for a publicly traded trNA diagnostic and therapeutic company, assisting management to identify key commercial interests and develop patent strategy; advises on research collaborations, leads patent diligence, and provides litigation and re-examination/IPR strategy.
  • Drafted and advised a Fortune 100 tobacco and food company on its distributor contracts for the launch of a new product line.
  • Advised on, drafted and negotiated intellectual property and drug promotion provisions on behalf of AtheroGenics, Inc. in a billion dollar license agreement with AstraZeneca for the global development and commercialization of AtheroGenics’ Phase III anti-inflammatory cardiovascular product candidate (cited as the largest biotech deal of 2005 by Bio World, nominated by Recap as one the five Breakthrough Alliances of 2006).
  • Advised on, drafted and negotiated intellectual property matters on behalf of Gilead Sciences, Inc. in its $525 million royalty buyout agreement with Emory University and Royalty Pharma for emtricitabine, a component of Gilead’s HIV drugs Truvada® and Emtriva® (cited by Emory President James Wagner as the largest known intellectual property deal at that time involving a U.S. university).
  • Advised on, drafted and negotiated multiple license agreements on behalf of Gilead Sciences, Inc., including with Japan Tobacco, Inc. for exclusive rights to develop and commercialize Japan Tobacco’s Phase I HIV integrase inhibitor, JTK-303; and with Achillion Pharmaceuticals for the research, development and commercialization of Achillion’s small molecule inhibitors for the treatment of the hepatitis C virus.
  • Represented a French pharmaceutical company in negotiating the terms of a license, manufacturing and supply agreement with its U.S. partner to develop and commercialize its billion-dollar drug in a fixed dose combination with a drug supplied by a third-party pharmaceutical company.
  • Negotiated numerous research agreements with universities, the NIH and non-profit organizations.
  • Advised clients, drafted and negotiated multiple agreements for the development and licensing of new software, hardware and consumer products.
  • Managed plant genomics patent portfolio for Monsanto, LLC and developed legal strategy on novel patent procurement issues, including challenges to USPTO restriction practice, and participating on behalf of Monsanto Company in its appeal regarding the utility of expressed sequence tags (ESTs), decided in In re Fisher, 421 F.3d 1365 (Fed. Cir. 2005).
  • Represented an HIV technology company in performing intellectual property due diligence in its acquisition of a competitor.
  • Performed multiple patent estate reviews and intellectual property due diligence on behalf of AOL, Inc. in its acquisitions of various internet technology companies.
  • Performed IP diligence on behalf of multiple U.S. biotechnology companies and advised on the desirability of potential acquisition target companies in Europe.
  • Represented defendant, a microprocessor company, in a complex patent infringement suit involving computer systems architecture for personal computers.
  • Represented plaintiff, a multinational innovator drug company, in an ANDA action to prevent generic competition by five generic drug companies.
  • Represented plaintiff in a trade secret action in a suit to stop misappropriation by former employees.

Related News

03/20/2017
Logue joins IP group at Lewis Roca Rothgerber Christie
Law firm's Los Angeles and Silicon Valley offices add Of Counsel to growing practice group

Presentations

  • Panelist, "Intellectual Property in the Biotech Industry," Women In Bio, November 2016
  • Presenter, "Moving Technology from Practice to Market," Los Angeles Biomedical Research Institute, August 2013.
  • Moderator, "Virtual Drug Development: The New Paradigm or Another Fad?," BIOCOM CRO Initiative Series, August 2012
  • Moderator, "When Science And Politics Collide: Regenerative Medicine & Stem Cell Research," Mid-Atlantic BIO Conference, October 2006
  • Presenter, "Protecting Your Intellectual Property: A Small Business Perspective," December 2005 

Article

  • "Drafting Patents for Litigation and Licensing," October 2008

Blog

Distinctions

  • American Bar Association Biotechnology Committee - Subcommittee Chair for Patent Restriction Practice, 2004-2005
  • Women In Bio - Chair, Southern California Chapter Development - Program Committee Member, 2002-2009 and Membership Committee Member 2012, 2012-2014

Other Info

Education

J.D., University of Michigan Law School, 2000
B.S., University of Michigan, 1997, Biochemistry

Bar Admissions

California, 2012
New York, 2012
Washington, DC, 2001
U.S. Patent and Trademark Office, 2001

Court Admissions

U.S. Court of Appeals, Federal Circuit, 2005
U.S. District Court, District of Columbia, 2005
U.S. Court of Appeals, Fourth Circuit, 2004